NEW BRUNSWICK, N.J., Oct. 28, 2013 /PRNewswire-USNewswire/ -- Researchers from GeneAssess, Inc., a Foundation Venture Capital Group portfolio company, announce the publication of the genetic studies that led to the identification of the FRY gene as a breast cancer susceptibility suppressor gene.
"We see great promise in Dr. Zarbl's discovery of the FRY gene and how it might be used to affect the diagnosis and treatment of aggressive breast cancers," noted James M. Golubieski, president of Foundation Venture Capital Group. "We are excited about helping to advance his work and bring his ideas to commercialization."
The studies, which appear in the online journal PLOS ONE (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0070930), are the culmination of more than 12 years of research performed by Dr. Helmut Zarbl, founder of GeneAssess, Inc.
"The current focus of GeneAssess is dedicated to the discovery, development and commercialization of novel high value diagnostic tests that help physicians diagnose, treat and improve outcomes for cancer patients," explained Dr. Zarbl, who is also a professor of environmental and occupational medicine at Rutgers Robert Wood Johnson Medical School and the associate director for the Public Health Sciences Division at The Rutgers Cancer Institute of New Jersey.
The studies featured in PLOS ONE examined why some rat strains are almost completely resistant to cancer, while other strains develop mammary carcinomas at a very high frequency when exposed to chemical carcinogens, hormones or radiation during the onset of puberty. To find the genes underlying this difference, Dr. Zarbl and his research team performed genetic crosses between a sensitive and resistant strain and examined wh
|SOURCE Foundation Venture Capital Group|
Copyright©2012 PR Newswire.
All rights reserved